Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence

Liver International

Volumn 23, Issue 1, 2003, Pages 45-53

  Pessione, F ^a   Ramond, M J ^a   Peters, L ^a   Pham, B N ^a   Batel, P ^a   Rueff, B ^a   Valla, D C ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Alcoholic cirrhosis; Alcoholic hepatitis; Prognosis; Survival; Tobacco

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; PREDNISOLONE;

ADULT; AGE; AGED; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CODING; PREDICTION; RISK FACTOR; SMOKING; SMOKING CESSATION; SURVIVAL; ALCOHOL LIVER CIRRHOSIS; DRINKING BEHAVIOR; EVALUATION; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ALCOHOL DRINKING; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SMOKING; SURVIVAL RATE; TEMPERANCE;

EID: 0037532347     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.01804.x     Document Type: Article

References (36)

1. Adler M, Verset D, Bouhdid H, et al. Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score. J Hepatol 1997; 26: 642-9.
2. Ekindjian O, Devanlay M, Duchassaing G, et al. Multivariate analysis of clinical and biological data in cirrhotic patients: application to prognosis. Eur J Clin Invest 1981; 11: 213-20.
3. Orrego H, Israel Y, Blake J, et al. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983; 3: 896-905.
4. Poynard T, Barthelemy P, Fratte S, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. Lancet 1994; 344: 502-7.
5. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
6. Kamath P S, Wiesner R H, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
7. Powell W, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Am J Med 1968; 44: 406-20.
8. Saunders J B, Walters J R F, Davies P, Paton A. A 20-year prospective study of cirrhosis. Br Med J 1981; 282: 263-6.
9. Borowsky S, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80: 1405-9.
10. Kobayashi M, Watanabe A, Nakatsukasa H, et al. Effect of continued drinking on prognosis of alcoholic liver cirrhosis. Acta Med Okayama 1983; 37: 525-7.
11. Soterakis J, Resnick R, Iber F. Effect of alcohol abstinence on survival in cirrhotic portal hypertension. Lancet, 1973; 65-7.
12. Chedid A, Mendenhall C, Gartside P, et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group Am J Gastroenterol 1991; 86: 210-6.
13. Orrego H, Blake J, Blendis L, et al. Prognostic of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92: 208-14.
14. Mathurin P, Mendenhall C, Carithers R L, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomised placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-7.
15. Pugh R N, Murray-Lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
16. Pham B N, Musset L. Hepatitis C. Screening tools. Gastroenterol Clin Biol 1997; 21: S130-9.
17. Schlichting P, Juhl E, Poulsen H, et al. Alcoholic hepatitis superimposed on cirrhosis. Clinical significance and effect of long-term prednisone treatment. Scand J Gastroenterol 1976; 11: 305-12.
18. Ramond M J, Poynard T, Rueff B, et al. A randomised clinical trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-12.
19. Sun G, Shook T, Kay G. Inappropriate use of bi-variable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996; 49: 907-16.
20. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and oesophageal varices. An analysis of data and prognostic factors in 589 patients from four randomised clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324: 1532-8.
21. de Franchis R, Vitagliano P, Agape D, et al. Eradication of oesophageal varices by endoscopic sclerotherapy: how much is enough? Gastrointest Endoscopy 1988; 34: 395-9.
22. Levacher S, Letourmelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8.
23. Cales P, Oberti F. Strategy for haemostatic treatment of haemorrhages caused by rupture of oesophageal and gastric varices. Gastrenterol Clin Biol 1995; 19: B1-9.
24. Burroughs A, Bosch J. Signes cliniques et traitement des episodes hemorragiqueschez le cirrhotiques. In: Benhamou J, Bircher J, McIntyre N, Rizzetto M, Rodes J, eds. Hepatologie clinique. Paris: Flammarion, Medicine-Sciences, 1993; 408-25
25. Smith J L, Graham D Y. Variceal haemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82: 968-73.
26. Burroughs A, Mezzanotte G, Phillips A, et al. Cirrhotics with variceal haemorrhage: the importance of the time interval between admission and the start of analysis for survival and re-bleeding rates. Hepatology 1989; 9: 801-7.
27. Shiomi S, Kuroki T, Minamitani S, et al. Effect of drinking on the outcome of cirrhosis in patients with hepatitis B or C. J Gastroenterol Hepatol 1992; 7: 274-6.
28. Mendenhall C L, Seeff L, Diehl A M, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group. Hepatol 1991; 14: 581-9.
29. Takase S, Tsutsumi M, Kawahara H, et al. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology 1993; 17: 9-13.
30. Thun M, Peto R, Lopez A, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997; 337: 1705-14.
31. Batel P, Pessione F, Maitre C, et al. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 1995; 90: 977-80.
32. Corrao G, Lepore A, Torchio P, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for Study Chronic Liver. Dis Eur J Epidemiol 1994; 10: 657-64.
33. Klatsky A, Armstrong M, Friedman G. Coffe, tea and mortality. Ann Epidemiol 1993; 3: 375-81.
34. Yu M, Hsu F, Sheen I, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039-47.
35. Balansky R, Izzoti A, Scatolini L, et al. Induction by carcinogens and chemoprevention by N-Acetylcysteine of adducts to mitochondrial DNA in rat organs. Cancer Res 1996; 56: 1642-7.
36. Bölükbas Ö Z, Kabasakal G, Keyer Uysal M, et al. Hepatocyte damage caused by nicotine alone and in combination with alcohol. Gastroenterology 1998; 114: A1318-9.